- |||||||||| brivaracetam / Generic mfg.
Clinical, P3 data, Retrospective data, Journal, HEOR: Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures. (Pubmed Central) - Nov 27, 2022
P3
The balance between efficacy, tolerability, and HRQOL was most favorable in patients with focal seizures who had been exposed to one or two ASMs before BRV initiation. However, patients exposed to ≥7 ASMs before BRV initiation also benefitted from long-term adjunctive BRV treatment.
- |||||||||| brivaracetam / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study (clinicaltrials.gov) - Nov 14, 2022
P=N/A, N=200, Active, not recruiting,
Among patients with focal seizures in LTC in the US, initiation of ESL versus BRV was associated with significant reductions in all-cause and epilepsy-specific pharmacy and total costs compared with initiation of BRV. Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Feb 2023 | Trial primary completion date: Jul 2022 --> Dec 2022
- |||||||||| brivaracetam / Generic mfg.
Long-term outcomes of treatment with BRIVIACT® (brivaracetam) and what it means in the real-world (Davidson Ballroom A, Level 1M) - Nov 13, 2022 - Abstract #AES2022AES_559;
Understand how the different methodologies used to calculate retention rates introduce biases and difficulties in making any comparisons between the ASMs4. Discover the RW retention rates of BRIVIACT, what those mean in the RW setting, including reasons for discontinuations, adverse events leading to discontinuations, retention rates in various subpopulations, and the makeup of study population as a potential factor affecting the retention rates'
- |||||||||| brivaracetam / Generic mfg.
Review, Journal: Narrative review of brivaracetam for genetic generalized epilepsies. (Pubmed Central) - Nov 5, 2022
Further and controlled studies are needed. According to our review, brivaracetam is a valid treatment alternative in patients with genetic generalized epilepsies capable of improving patients' quality of life by reducing seizure frequency with minimal adverse effects.
- |||||||||| Fycompa (perampanel) / Eisai
Review, Journal: Paediatric status epilepticus (Pubmed Central) - Oct 18, 2022
Early identification and treatment of a prolonged crisis are essential to prevent progression to status. Although with fewer sequelae than in adults, status epilepticus in children represents a cause of mortality of up to 3-5%, while 25% of them will develop subsequent epilepsy, as well as a considerable percentage of neurological sequelae.
- |||||||||| Tenofovir Associated Hyaline Arteriosclerosis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2440;
Introduction Tenofovir Disoproxil Fumarate (TDF) is associated with various patterns of kidney injury...Case Description A 40-year-old Caucasian male with a history of epilepsy on Lacosamide and Brivaracetam, hepatitis C (HCV) treated with Sofosbuvir/Velpatasvir (SV), cutaneous sarcoid on Hydroxychloroquine, pre-exposure prophylaxis on Emtricitabine and TDF for seven years presented to nephrology clinic with asymptomatic elevation in creatinine (CR)...Blood pressures were normal and the only known potential nephrotoxic agents were TDF and Omeprazole...Moreover, the twelve weeks of increased TDF exposure may have led to microvascular changes that ultimately resulted in HA. To our knowledge, this is the first case of HA associated with TDF in a young patient without any known risk factors.
- |||||||||| brivaracetam / Generic mfg.
A case report of psychiatric comorbidities in epilepsy (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1168;
As psychiatric history initiates follow-up at Child and Youth Mental Health Center since 2014 due to emotional dysregulation, difficulties in relationships with peers and behaviour alterations when faced with limits, and mild intellectual disability (IQM 68). During his hospital stay, an inter-consultation was done at Neurology service to assess the seizure component, and the complementary tests (CT, EEG, LP, blood analyses), concluded that the condition was compatible with a bitemporal epilepsy, so antiepileptic treatment with Brivaracetam 50 mg/12 hours is started. Until this last admission, this patient had not previously been followed up by neurology, since the psychotic clinic had always been related as a probable psychiatric origin, for which she had only undergone antipsychotic treatment...Acute treatment of epileptic psychosis involves a multidisciplinary approach with early involvement of specialized psychiatry. Adequate recognition and treatment of psychosis in epilepsy is essential for patient management due to its considerable burden of disease and quality of life.
- |||||||||| Fycompa (perampanel) / Eisai, Diacomit (stiripentol) / Biocodex, Meiji Seika, Fintepla (low-dose fenfluramine) / UCB
Review, Journal, Adverse events: Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. (Pubmed Central) - Oct 13, 2022
Bromide, felbamate and other sodium channel ASMs are discussed briefly...Cannabidiol, PER and pregabalin may be associated with improvements in sleep, LTG is associated with insomnia, while VPA, TPM, LEV, ZNS and LCM do not appear to have detrimental effects...Finally, we discuss how a variety of factors can affect mood, behaviour and cognition, and untangling the associations between the effects of the underlying syndrome and those of the ASMs can be challenging. In particular, there is enormous heterogeneity in cognitive, behavioural and developmental impairments that is complex and can change naturally over time; there is a lack of standardised instruments for evaluating these outcomes in developmental and epileptic encephalopathies, with a reliance on subjective evaluations by proxy (caregivers); and treatment regimes are complex involving multiple ASMs as well as other drugs.
- |||||||||| brivaracetam / Generic mfg.
Journal: A healthy outcome of a pregnant woman with drug-resistant juvenile myoclonic epilepsy treated with brivaracetam. (Pubmed Central) - Oct 13, 2022
In particular, there is enormous heterogeneity in cognitive, behavioural and developmental impairments that is complex and can change naturally over time; there is a lack of standardised instruments for evaluating these outcomes in developmental and epileptic encephalopathies, with a reliance on subjective evaluations by proxy (caregivers); and treatment regimes are complex involving multiple ASMs as well as other drugs. No abstract available
- |||||||||| Review, Journal: Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force (Pubmed Central) - Oct 11, 2022
High infant levels (30% up to 100% of maternal serum concentrations) have been reported with ethosuximide, phenobarbital and zonisamide...It is concluded that breastfeeding should in general be encouraged in women taking ASMs, given the well-established benefits of breastfeeding with regard to both short- and long-term infant health in the general population. Counselling needs to be individualized including information on the current knowledge regarding the woman's specific ASM treatment.
- |||||||||| levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Altered neuronal cooperativity in Alzheimer's disease (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_12498;
Currently, we seek to understand the relationship between sleep deprivation at different ages and AD pathology. Moreover, we are working on comparing these results with human iPS-derived neuronal networks for better insight on the mechanisms described above.
- |||||||||| Fycompa (perampanel) / Eisai, Diacomit (stiripentol) / Biocodex, Meiji Seika, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Journal: Stability Indicating Methods for Determination of Third Generation Antiepileptic Drugs and Their Related Substances. (Pubmed Central) - Oct 7, 2022
A number of these antiepileptic drugs were found to have had a small number of studies related to their stability and for the detection of impurities. The presentation of the current level of research on third generation antiepileptic drugs highlights the need for new stability and safety studies that are necessary to develop new pharmaceutical products containing these drugs.
- |||||||||| brivaracetam / Generic mfg.
Journal: Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center. (Pubmed Central) - Oct 5, 2022
Brivaracetam was effective at a broad range of doses in managing drug-resistant epilepsy across various phenotypes, but less effective than LEV in those who switched due to poor tolerability on LEV. There were no new tolerability issues, but 77% of the individuals experiencing side effects on BRV also experienced similar side effects on LEV.
- |||||||||| levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Biomarker, Clinical, Preclinical, Retrospective data, Review, Journal: Anti-epileptogenic effects of synaptic vesicle protein 2A modulation in a mouse model of Alzheimer's disease. (Pubmed Central) - Sep 30, 2022
Brivaracetam treatment displayed marked anti-epileptogenic effects in both aged and young Tg2576 mice, including when treatment is ceased prior to initiating kindling. Targeting SV2A might represent a strategy for prevention of epilepsy in patients with Alzheimer's disease.
- |||||||||| Journal: Current and future pharmacotherapy options for drug-resistant epilepsy. (Pubmed Central) - Sep 30, 2022
For specific epilepsy syndromes, XEN 496 is under Phase III development for potassium voltage-gated channel subfamily Q member 2 developmental and epileptic encephalopathy (KCNQ2-DEE), carisbamate is under Phase III development for LGS and Ganaxolone under Phase III development for TSC. Finally, in preclinical models several molecular targets including inhibition of glycolysis, neuroinflammation and sodium channel inhibition have been identified in animal models although further data in animal and later human studies are needed.
- |||||||||| Fycompa (perampanel) / Eisai
Journal: Pharmacotherapeutic management of seizures in patients with Angleman syndrome. (Pubmed Central) - Sep 29, 2022
Although the potential utility of several other ASMs(valproate, topiramate, lamotrigine, ethosuximide, clonazepam) has been well documented for some time, the treatment landscape may rapidly evolve due to the availability of newer and better tolerated ASMs(cannabidiol oil, brivaracetam, perampanel). In addition, a better understanding of the underlying pathogenesis and the development of molecular therapeutics offer hope for precision therapies for seizures.
- |||||||||| rifampicin / Generic mfg., brivaracetam / Generic mfg.
PK/PD data, Journal: Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes. (Pubmed Central) - Sep 10, 2022
When coadministered with RIF, the model predicted the most significant magnitude of drug-drug interaction (DDI) in EMs, while the exposure change of BRV was minimal in PMs. Referencing the recommended concentration for therapeutic drug monitoring (TDM), we concluded that the current clinical maintenance dose of BRV is acceptable regardless of CYP2C19 polymorphisms and coadministration with RIF.
- |||||||||| Fycompa (perampanel) / Eisai, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Efficiency of Third-Generation Antiseizure Medications in Spain for Drug-Resistant Epilepsy: A Cost-per-Number Needed to Treat Analysis (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1623;
The findings show a clear link between the efficacy of third-generation ASMs available in Spain for the treatment of FOS in patients with DRE and their efficiency, facilitating determination of drug’s value contribution and decision-making in Spain. Cenobamate presents the lowest cost per NNT relative to seizure freedom, proving to be the most efficient option compared to third-generation alternatives.
- |||||||||| brivaracetam / Generic mfg.
Review, Journal: Intravenous Brivaracetam in the Management of Acute Seizures in the Hospital Setting: A Scoping Review. (Pubmed Central) - Aug 24, 2022
Cenobamate presents the lowest cost per NNT relative to seizure freedom, proving to be the most efficient option compared to third-generation alternatives. IV BRV shows effectiveness, and is generally well tolerated in the management of acute seizures in hospitalized patients where rapid administration is needed, representing a clinically relevant antiseizure medication for potential use in the critical care setting.
- |||||||||| Review, Journal: Antiseizure Drugs and Movement Disorders. (Pubmed Central) - Aug 6, 2022
Although little information is available on the adverse effects or benefits on movement disorders of newer antiseizure drugs (such as brivaracetam, cenobamate, eslicarbazepine, lacosamide, and rufinamide), the evidence collected in this review should guide the choice of antiseizure drugs in patients with concomitant epilepsy and movement disorders. Finally, these notions can lead to a better understanding of the mechanisms involved in the pathophysiology and treatments of movement disorders.
- |||||||||| vixotrigine (BIIB074) / Biogen, GSK, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Journal: Pharmacotherapeutic Management of Trigeminal Neuropathic Pain: An Update. (Pubmed Central) - Jul 31, 2022
In real-world clinical practice, baclofen, cannabinoids, eslicarbazepine, levetiracetam, brivaracetam, lidocaine, misoprostol, opioids, phenytoin, fosphenytoin, pimozide, sodium valproate, sumatriptan, tizanidine, tocainide, tricyclic antidepressants, and vixotrigine are sometimes used, either as monotherapy or in combination...While there is no optimal pharmacotherapy for treating trigeminal neuropathy, advancements in our understanding of the underlying mechanisms of this condition and drug development indicate promise for NaV inhibitors, despite the fact that not all patients respond to them and they may have potentially treatment-limiting side effects. Nevertheless, better understanding of NaV channels may be important avenues for future drug development for trigeminal neuropathy.
- |||||||||| baclofen / Generic mfg., pregabalin / Generic mfg., brivaracetam / Generic mfg.
Review, Journal: Asymmetric Michael Addition in Synthesis of β-Substituted GABA Derivatives. (Pubmed Central) - Jul 1, 2022
In this review, we critically discuss the literature data reported on the preparation of substituted GABA derivatives using the Michael addition reaction as a key synthetic transformation. Special attention is paid to asymmetric methods featuring synthetically useful stereochemical outcomes and operational simplicity.
- |||||||||| Journal: Individualizing doses of antiepileptic drugs. (Pubmed Central) - Jun 22, 2022
We used Pubmed, Google Scholar and EMBASE database's to support our article. To ensure that the patient with seizure receives the best treatment in relation to their comorbidities, careful clinical-laboratory monitoring is necessary to maximize effectiveness while maintaining safety, especially in the case of polytherapy.
- |||||||||| Review, Journal: Impact of Antiseizure Medications on Appetite and Weight in Children. (Pubmed Central) - Jun 22, 2022
The ASM most robustly associated with increased appetite and/or weight gain is valproic acid; however, both pregabalin and perampanel may also lead to modest weight gain or increased appetite in children. Certain ASMs may impact both appetite and weight, which may lead to increased morbidity of the underlying disease and impaired adherence to the treatment regimen.
- |||||||||| brivaracetam / Generic mfg.
Journal: Brivaracetam for dyskinetic cerebral palsy. (Pubmed Central) - Jun 10, 2022
We report successful anesthetic management for general anesthesia with propofol and fentanyl and highly recommend their use in this kind of patients. No abstract available
|
